This article was originally published in Start Up
Executive SummaryParis-based Theraclion SAS has developed a non-surgical approach to treating hyperparathyroidism. The company's TH-One technology employs an externally applied converging beam of high-intensity focused ultrasound to create a rapid temperature rise in the extremely small parathyroid glands. Each pulse of energy produces a small lesion of coagulation, leading to destruction of the parathyroids.
You may also be interested in...
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.